bioMérieux S.A. (OTCMKTS:BMXMF - Get Free Report)'s share price traded up 3% on Friday . The stock traded as high as $103.56 and last traded at $103.56. 30 shares traded hands during trading, a decline of 49% from the average session volume of 59 shares. The stock had previously closed at $100.50.
Analyst Upgrades and Downgrades
Separately, UBS Group upgraded shares of bioMérieux to a "strong-buy" rating in a research report on Thursday, August 22nd.
Get Our Latest Research Report on bioMérieux
bioMérieux Stock Performance
The firm's 50 day moving average is $111.24 and its two-hundred day moving average is $107.50.
bioMérieux Company Profile
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Further Reading
Before you consider bioMérieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMérieux wasn't on the list.
While bioMérieux currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
